The treatments being investigated include vinblastine sulfate, which is given as an intravenous injection, and two oral medications called ulixertinib and tovorafenib. Participants may receive different combinations of these drugs depending on the specific part of the study they are assigned to. This approach allows for the testing of various treatment plans to see which ones work best and are safest.

During the study, the amount of medication provided may be adjusted to find the highest dose that can be taken safely. Regular monitoring occurs throughout the treatment period to observe how the body responds to the drugs and to check for any side effects. The study will evaluate how well the medications control the tumor over time.

Participants in the study will receive the medications in the form of capsules or tablets taken by mouth. The study will be conducted in two phases. In the first phase, the focus will be on determining the best dose of vorasidenib to use with temozolomide. In the second phase, the study will look at how well the combination works in controlling the tumor over a period of time. The study will also monitor the participants for any side effects or adverse reactions to the treatment.

The study aims to gather information on the progression of the disease and the overall survival of participants. It will also measure the levels of vorasidenib and its breakdown products in the blood, as well as the levels of temozolomide. The study is expected to continue until early 2028, with recruitment of participants starting in 2025. This research is important for understanding how these treatments can be used together to potentially improve outcomes for patients with IDH1 or IDH2 mutant gliomas.

The treatment involves receiving L19TNF through intravenous infusion alongside oral temozolomide capsules and radiation therapy. The purpose of this research is to determine if adding L19TNF to the standard treatment is safe and effective for patients with newly diagnosed glioblastoma.

The study is conducted in multiple phases to first establish the appropriate dose and then evaluate how well the treatment works. Throughout the study, patients will undergo regular medical check-ups, including brain scans to monitor their condition. The treatment combines different approaches to fighting the tumor: targeted therapy with L19TNF, chemotherapy with temozolomide, and radiation therapy.

The purpose of this study is to evaluate the safety and effectiveness of rapamycin in treating high-grade gliomas in children. Participants in the study will receive rapamycin and will be monitored for any side effects and how well the treatment works over time. The study will track the overall survival of participants, as well as how long they remain free from tumor progression or other events related to the disease. The study will also assess the overall response rate to the treatment, which includes measuring any changes in the tumor size or condition.

Throughout the study, researchers will carefully observe and record any adverse reactions to rapamycin, especially those that are more severe. The study aims to provide valuable information on the potential benefits and risks of using rapamycin for treating high-grade gliomas in children, contributing to the understanding and management of this challenging condition.

Participants in the study will receive either bevacizumab or dexamethasone over a period of 12 weeks. The study will monitor the participants’ response to the treatment, including any changes in their symptoms and overall health. The trial will also assess the cost-effectiveness of each treatment option. Throughout the study, participants will undergo regular assessments to track their progress and any side effects they may experience.

The trial aims to provide valuable information on the best treatment approach for patients with cerebral radiation necrosis following radiation therapy for high-grade glioma or brain metastases. By comparing bevacizumab and dexamethasone, the study seeks to improve the quality of life and health outcomes for individuals affected by this condition.

The purpose of the study is to see if the uPAR PET/MRI can effectively show the presence of gliomas and help differentiate between high-grade and low-grade gliomas. It also aims to distinguish between tumor progression and changes that occur after treatment. The study will observe how the uptake of the tracer relates to the levels of uPAR in the tumor, which is determined by examining tissue samples from the tumor.

Participants in the study will undergo the uPAR PET/MRI scan, and the results will be compared with tissue samples to assess the accuracy of the imaging. The study will also look at how the levels of uPAR in the tumor might relate to the patient’s survival over a period of 36 months. This research could provide valuable insights into the diagnosis and treatment planning for patients with glioma.

Participants in the study will receive different doses of L19TNF and lomustine to see which combination works best and has the fewest side effects. The study will last for a period of time, during which participants will have regular check-ups and tests to monitor their health and the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study aims to improve understanding of how these treatments can help people with glioblastoma, focusing on safety and effectiveness. Researchers will look at various outcomes, such as how long patients live after treatment and how long they remain free from cancer progression. The study will also monitor any side effects and how the body processes the treatments. This research hopes to provide valuable information that could lead to better treatment options for glioblastoma in the future.

The purpose of the study is to determine if adding Abemaciclib to the standard chemotherapy treatment with Temozolomide can provide additional benefits for patients who have been newly diagnosed with high-grade glioma and have already undergone radiotherapy. Radiotherapy is a treatment that uses high-energy rays to target and kill cancer cells. The study will compare the combination of Abemaciclib and Temozolomide to the use of Temozolomide alone.

Participants in the study will receive either the combination treatment or Temozolomide alone. The study will monitor the participants over a period to assess the effectiveness of the treatments. The goal is to see if the combination treatment can improve outcomes for patients with high-grade glioma. The study will involve regular check-ups, including lab tests and imaging of the tumor, to track the progress and effects of the treatment.

The first treatment approach combines two chemotherapy drugs – temozolomide and lomustine – followed by radiation therapy to part of the brain and additional chemotherapy if the disease progresses. The second approach starts with radiation therapy followed by a combination of three chemotherapy drugs: procarbazine, lomustine, and vincristine (known as PCV chemotherapy), with additional treatment options if the disease progresses.

During the study, doctors will monitor how well patients function in their daily activities, their thinking abilities, and their quality of life. These factors, along with survival time, will help determine which treatment approach works better. The medications used in this study are given either by mouth as capsules or through an intravenous line directly into the bloodstream.

Participants in the study will receive Temozolomide and will be monitored at the start, after six months, and after twelve months. These assessments will help researchers understand how the treatment affects patients’ mental and emotional well-being, as well as their overall quality of life. The information gathered will be used to develop future studies that may involve multiple research centers.

The study will collect data on various aspects of patients’ health, including their ability to think and remember, their emotional state, and their physical health. This information will help researchers form hypotheses for future research aimed at improving treatment and care for patients with diffuse low-grade gliomas. The study is designed to ensure that patients can participate and complete the necessary evaluations throughout the study period.

The purpose of the study is to see if this new treatment can be safely produced and given to children with these brain tumors, either alongside their regular treatment or after they have completed other therapies. The study will also look at how safe the treatment is for the patients. During the study, participants will receive the treatment through a series of injections over a period of time. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the new treatment.

Throughout the study, researchers will monitor the patients to see how they respond to the treatment and to check for any side effects. The study aims to understand how the treatment affects the patients’ overall health and quality of life. This research is important for finding new ways to help children with these difficult-to-treat brain tumors.

Participants in the study will receive injections of these imaging agents, and then undergo PET scans. The study will look at how the images from the two different agents compare in terms of showing the tumor’s size and how the agent spreads in the brain. This will help doctors understand which agent might be more effective for certain types of brain tumors. The study is designed to be open-label, meaning both the participants and the researchers know which agent is being used.

The trial aims to gather information over a period of time to see if there is a significant correlation between the results from the two agents. It will also assess how accurately these agents can differentiate between tumor growth and changes related to previous treatments. This information could be valuable in improving the diagnosis and treatment planning for patients with brain tumors.

The purpose of the study is to see if the new treatment with Trametinib is better than the standard treatment with Vinblastine in managing the disease over a period of 18 months. Participants in the study will be randomly assigned to receive either the daily oral Trametinib or the weekly intravenous Vinblastine. The study will last for a total of 72 weeks, during which time the participants will be closely monitored by healthcare professionals. The study aims to improve the current treatment options for patients with this type of brain tumor.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their treatment. The study will also collect information on how well the tumor responds to the treatment and any side effects that may occur. The goal is to determine if the new treatment can provide better outcomes for patients with low-grade glioma, potentially leading to improved survival rates and quality of life. This research is important for advancing the understanding and treatment of low-grade gliomas in children and young adults.

The purpose of the study is to evaluate how well Larotrectinib can control the disease in young children with newly diagnosed high-grade glioma that has the NTRK fusion. The study will also look at the safety of using Larotrectinib alone and in combination with other chemotherapy drugs. These chemotherapy drugs include Carboplatin, Methotrexate, Vincristine sulfate, Cyclophosphamide monohydrate, and Etoposide phosphate. Some of these drugs are given through an injection into a vein, known as intravenous administration.

Participants in the study will receive Larotrectinib for a certain period, and their response to the treatment will be monitored. The study will also assess any side effects that may occur. The trial aims to provide valuable information on the effectiveness and safety of Larotrectinib for treating this type of brain cancer in children.

Participants in the study will take lenvatinib in the form of a capsule, which is taken by mouth. The study will monitor the response of the tumors to the treatment over a period of time, specifically looking at the changes in the size of the tumors and any side effects experienced by the participants. The study aims to determine the effectiveness of lenvatinib in shrinking the tumors and improving the condition of the patients.

The study will last for several weeks, during which participants will receive regular check-ups and assessments to track their progress. The researchers will use specific criteria to evaluate the response of the tumors to the treatment, ensuring that the results are accurate and reliable. This study is an important step in finding better treatment options for young patients with these challenging types of cancer.

The purpose of the study is to see if vorasidenib can help slow down the growth of the tumor when compared to a placebo. Participants in the study will be randomly assigned to receive either the vorasidenib tablets or placebo tablets. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, which is known as a double-blind study. The treatment period can last up to 96 weeks, and participants will have regular check-ups and imaging tests like MRI to monitor the tumor’s response to the treatment.

Throughout the study, the safety of vorasidenib will be closely monitored by checking for any side effects or changes in health. Participants will also have their blood tested to understand how the body processes the medication. The study aims to provide valuable information on whether vorasidenib can be an effective treatment option for people with Grade 2 glioma with IDH1 or IDH2 mutations.

Participants in the study will receive an injection of Dopacis and then undergo a PET scan. This scan will help doctors understand the characteristics of the tumor better. The study will look at how the tumor absorbs the 18F-FDOPA over time, which can provide important information about the nature of the tumor. This information will be compared to the results of a biopsy or surgery that participants will have within six months of the scan.

The study aims to improve the care of patients with Low Grade Glioma by providing more detailed information about their tumors. This could help doctors make better decisions about treatment options. The trial will continue until 2026, and it is hoped that the findings will lead to better diagnostic tools for these types of brain tumors.

The purpose of the study is to find out which combination of these treatments is safe and effective for young patients with these challenging types of cancer. In the first stage of the study, researchers will determine which of the three chemotherapy regimens is safe to use with Nivolumab. The regimens being tested are: Cyclophosphamide and Vinblastine; Capecitabine alone; and a combination of Cyclophosphamide, Vinblastine, and Capecitabine. In the second stage, the study will focus on the most promising regimen from the first stage, with or without Nivolumab, to see how well it works in preventing the cancer from getting worse.

Participants in the study will receive their treatments either through an intravenous method, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study will monitor the participants over time to assess the safety of the treatments and their effectiveness in controlling the cancer. The study aims to provide valuable information that could lead to better treatment options for children and teenagers facing these difficult cancers.

The purpose of the study is to evaluate how safe and tolerable this treatment is for patients, as well as how effective it is in treating the cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor patients over a period of time to see how they respond to the treatment and to check for any side effects. The study will also look at how the treatment affects the cancer’s progression and the overall survival of the patients.

Throughout the study, various assessments will be conducted, including imaging tests like MRI to evaluate the tumor’s response to the treatment. The study will also assess the impact of the treatment on patients’ quality of life and their ability to perform daily activities. The goal is to gather comprehensive information about the treatment’s benefits and any potential risks, helping to determine its suitability for treating this type of brain cancer.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.